Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study

被引：9
|
作者：
Luebbert, Michael [1 ]
Rueter, Bjorn [1 ]
Claus, Rainer
Schmid, Mathias [2 ]
Germing, Ulrich [3 ]
Eimeracher, Hartmut [4 ]
Ganser, Arnold [5 ]
Platzbecker, Uwe [6 ]
Galm, Oliver [7 ]
Brugger, Wolfram [8 ]
Heil, Gerhard [9 ]
Wijermans, Pierre W. [10 ]
Pfeifer, Dietmar [1 ]
Schmoor, Claudia [11 ]
Doehner, Hartmut [2 ]
机构：
[1] Univ Hosp, Freiburg, Germany
[2] Univ Hosp, Ulm, Germany
[3] Univ Hosp, Dusseldorf, Germany
[4] Catholic Hosp, Hagen, Germany
[5] Univ Hosp, Hannover, Germany
[6] Univ Hosp, Dresden, Germany
[7] Univ Hosp, Aachen, Germany
[8] Hospital, Villigen Schwenningen, Germany
[9] Hospital, Ludenscheid, Germany
[10] Leyenburg Hosp, The Hague, Netherlands
[11] Univ Hosp, Ctr Clin Trials, Freiburg, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.300.300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
300
引用
收藏
页码：95A / 95A
页数：1
相关论文
共 50 条
  • [1] Continued low-dose decitabine (DAC) is an active first-line treatment of older AML patients:: First results of a multicenter phase II study.
    Lübbert, M
    Rüter, B
    Schmid, M
    Knipp, S
    Germing, U
    Dobbelstein, C
    Eimermacher, H
    Deschler, B
    Claus, R
    Schlenk, R
    Ganser, A
    Döhner, H
    Schmoor, C
    Henss, H
    BLOOD, 2005, 106 (11) : 527A - 527A
  • [2] Continued Treatment with An Outpatient Maintenance Schedule of Decitabine in Older AML Patients Ineligible for Induction Chemotherapy: Results of the 00331 Phase II Multicenter Trial
    Luebbert, Michael
    Schmid, Mathias
    Rueter, Bjorn
    Germing, Ulrich
    Rethwisch, Volker
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Wijermans, Pierre W.
    Schmoor, Claudia
    Doehner, Hartmut
    BLOOD, 2008, 112 (11) : 1018 - 1019
  • [3] Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
    Cashen, Amanda F.
    Schiller, Gary J.
    O'Donnell, Margaret R.
    DiPersio, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 556 - 561
  • [4] Phase II study of low-dose decitabine for the front-line treatment of older patients with acute myeloid leukemia (AML).
    Cashen, Amanda
    Schiller, Gary J.
    Larsen, Julie S.
    Cullen, Michael T., Jr.
    DiPersio, John F.
    BLOOD, 2006, 108 (11) : 561A - 562A
  • [5] PHASE II STUDY OF CLADRIBINE AND LOW-DOSE ARAC ALTERNATING WITH DECITABINE IN OLDER PATIENTS WITH AML
    Kadia, T.
    Cortes, J.
    Borthakur, G.
    Jabbour, E.
    Daver, N.
    Pemmaraju, N.
    Verstovsek, S.
    Burger, J.
    Ferrajoli, A.
    Wierda, W.
    Konopleva, M.
    DiNardo, C.
    Jain, N.
    Brandt, M.
    Tuttle, C.
    Wang, X.
    Ravandi, F.
    Garcia-Manero, G.
    Kantarjian, H.
    HAEMATOLOGICA, 2016, 101 : 42 - 42
  • [6] Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Daver, Naval
    Jabbour, Elias
    Pemmaraju, Naveen
    Verstovsek, Srdan
    Burger, Jan A.
    Wierda, William G.
    Konopleva, Marina
    DiNardo, Courtney D.
    Jain, Nitin
    Brandt, Mark
    Tuttle, Carla
    Wang, Xuemei
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2014, 124 (21)
  • [7] A phase II study of weekly low-dose docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
    Chen, J. S.
    Shen, W. C.
    Chen, Y. Y.
    Huang, J. S.
    Yeh, K. Y.
    Chen, P. T.
    Hsu, H. C.
    Lin, Y. C.
    Wang, H. M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 375 - 376
  • [8] A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
    Luebbert, Michael
    Rueter, Bjoern H.
    Claus, Rainer
    Schmoor, Claudia
    Schmid, Mathias
    Germing, Ulrich
    Kuendgen, Andrea
    Rethwisch, Volker
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Heil, Gerhard
    Hackanson, Bjoern
    Deschler, Barbara
    Doehner, Konstanze
    Hagemeijer, Anne
    Wijermans, Pierre W.
    Doehner, Hartmut
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 393 - 401
  • [9] Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML
    Thomas, X. G.
    Dmoszynska, A.
    Wierzbowska, A.
    Kuliczkowski, K.
    Mayer, J.
    Shelekhova, T.
    Gau, J.
    Chou, W.
    Buckstein, R.
    Cermak, J.
    Kuo, C.
    Rocafiguera, A. O.
    Koza, V.
    Ravandi, F.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Irinotecan and low-dose capecitabine combination as first-line chemotherapy in advanced or metastatic gastric cancer: results of a phase II study
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Naser, F.
    Youness, F.
    Ghosn, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 383 - 383
12345